{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:01:11Z","timestamp":1784826071395,"version":"3.55.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ymthe.2025.08.050","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:17:09Z","timestamp":1756826229000},"page":"6350-6365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of an AAV-delivered microRNA gene therapy for myotonic dystrophy type 1"],"prefix":"10.1016","volume":"33","author":[{"given":"Giulio S.","family":"Tomassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Magli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Rapaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameer","family":"Khader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith L.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"O\u2019Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kollu","family":"Nageswara Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel T.","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-8749","authenticated-orcid":false,"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.050_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000524734","article-title":"Global Prevalence of Myotonic Dystrophy: An Updated Systematic Review and Meta-Analysis","volume":"56","author":"Liao","year":"2022","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ymthe.2025.08.050_bib2","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.050_bib3","series-title":"StatPearls [Internet]","article-title":"Myotonic Dystrophy [Updated 2023 Jun 26]","author":"Vydra","year":"2025"},{"key":"10.1016\/j.ymthe.2025.08.050_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.08.050_bib5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.1546325","article-title":"Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene","volume":"255","author":"Mahadevan","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.050_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/355548a0","article-title":"Cloning of the essential myotonic dystrophy region and mapping of the putative defect","volume":"355","author":"Aslanidis","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.050_bib7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/355547a0","article-title":"Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy","volume":"355","author":"Buxton","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.050_bib8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.1546326","article-title":"An unstable triplet repeat in a gene related to myotonic muscular dystrophy","volume":"255","author":"Fu","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.050_bib9","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","article-title":"Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy","volume":"19","author":"Miller","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.08.050_bib10","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1093\/hmg\/10.19.2165","article-title":"Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2","volume":"10","author":"Mankodi","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib11","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1074\/jbc.M410781200","article-title":"MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1","volume":"280","author":"Dansithong","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.08.050_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","article-title":"Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing","volume":"10","author":"Charlet-B","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2025.08.050_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0140-6736(92)90729-M","article-title":"Unstable DNA sequence in myotonic dystrophy","volume":"339","author":"Harley","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.050_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp.2008.158261","article-title":"The myotonic dystrophies: diagnosis and management","volume":"81","author":"Turner","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2025.08.050_bib15","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.050_bib16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification","volume":"172","author":"De Antonio","year":"2016","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ymthe.2025.08.050_bib18","unstructured":"Cheng, S., Jacobo, S.M., Moriguchi, T., O'riordan, C., and Ruan, G. (2023). TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY. pat #Wo2023196862a1."},{"key":"10.1016\/j.ymthe.2025.08.050_bib19","unstructured":"Loiler, S.A. (2019). INCREASING TISSUE SPECIFIC GENE DELIVERY BY CAPSID MODIFICATION. pat #Wo2019178412a1."},{"key":"10.1016\/j.ymthe.2025.08.050_bib20","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0168-9525(92)90081-E","article-title":"Making muscle in mammals","volume":"8","author":"Buckingham","year":"1992","journal-title":"Trends Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1006\/jmcc.1996.0112","article-title":"Alpha-myosin heavy chain gene regulation: delineation and characterization of the cardiac muscle-specific enhancer and muscle-specific promoter","volume":"28","author":"Molkentin","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1101\/gr.9.5.506","article-title":"Inventory of high-abundance mRNAs in skeletal muscle of normal men","volume":"9","author":"Welle","year":"1999","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41467-018-08283-7","article-title":"Next-generation muscle-directed gene therapy by in silico vector design","volume":"10","author":"Sarcar","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.08.050_bib25","series-title":"Targeted Gene Therapy for DM-1 Myotonic Dystrophy","author":"Cheng","year":"2023"},{"key":"10.1016\/j.ymthe.2025.08.050_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.omtm.2019.09.001","article-title":"A Muscle Hybrid Promoter as a Novel Tool for Gene Therapy","volume":"15","author":"Piekarowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.08.050_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.32607\/actanaturae.11063","article-title":"Muscle-Specific Promoters for Gene Therapy","volume":"13","author":"Skopenkova","year":"2021","journal-title":"Acta Naturae"},{"key":"10.1016\/j.ymthe.2025.08.050_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/hum.2014.115","article-title":"Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade","volume":"26","author":"Han","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/hum.2017.062","article-title":"Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy","volume":"29","author":"Potter","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib31","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkl143","article-title":"Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC\/miR-155","volume":"34","author":"Chung","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib33","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/mt.2011.292","article-title":"Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles","volume":"20","author":"Mueller","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib34","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.94.14.7388","article-title":"Expansion of a CUG trinucleotide repeat in the 3\u2032 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts","volume":"94","author":"Davis","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.050_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1083\/jcb.128.6.995","article-title":"Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues","volume":"128","author":"Taneja","year":"1995","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib36","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","article-title":"Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy","volume":"15","author":"Lin","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1126\/science.280.5364.737","article-title":"Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy","volume":"280","author":"Philips","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.050_bib38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ana.23992","article-title":"Splicing biomarkers of disease severity in myotonic dystrophy","volume":"74","author":"Nakamori","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib39","author":"Biosciences"},{"key":"10.1016\/j.ymthe.2025.08.050_bib41","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/nar\/gkab022","article-title":"Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy","volume":"49","author":"Tanner","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/hmg\/ddu492","article-title":"Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins","volume":"24","author":"Kino","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib43","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1038\/s41467-018-06206-0","article-title":"Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies","volume":"9","author":"Antoury","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.08.050_bib44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.nbd.2014.05.026","article-title":"LDB3 splicing abnormalities are specific to skeletal muscles of patients with myotonic dystrophy type 1 and alter its PKC binding affinity","volume":"69","author":"Yamashita","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.08.050_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221149781","article-title":"Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy","volume":"16","author":"Goedeker","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ymthe.2025.08.050_bib46","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.08.050_bib47","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/mt.2011.22","article-title":"Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer","volume":"19","author":"Pulicherla","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib49","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1128\/JVI.01288-06","article-title":"Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes","volume":"80","author":"Wu","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nbt.1599","article-title":"Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle","volume":"28","author":"Asokan","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib51","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003043","article-title":"Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus","volume":"8","author":"Huguet","year":"2012","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib53","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.nmd.2013.07.014","article-title":"Longitudinal in vivo muscle function analysis of the DMSXL mouse model of myotonic dystrophy type 1","volume":"23","author":"Decostre","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.08.050_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1257682","article-title":"Electrophysiological basis of cardiac arrhythmia in a mouse model of myotonic dystrophy type 1","volume":"14","author":"Ginjupalli","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111874","article-title":"Cardiac Pathology in Myotonic Dystrophy Type 1","volume":"22","author":"Mahadevan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.08.050_bib56","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-022-31770-x","article-title":"A reference single-cell regulomic and transcriptomic map of cynomolgus monkeys","volume":"13","author":"Qu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.08.050_bib57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.115.226969","article-title":"Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1","volume":"355","author":"Pandey","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.08.050_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2021.07.257","article-title":"MYOTONIC DYSTROPHY: EP. 233 The FORCETM platform achieves durable knockdown of toxic human nuclear DMPK RNA and correction of splicing in the hTFR1\/DMSXL mouse model","volume":"31","author":"Zanotti","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.08.050_bib60","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41434-022-00316-7","article-title":"Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1","volume":"29","author":"Ait Benichou","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib61","author":"Biosciences"},{"key":"10.1016\/j.ymthe.2025.08.050_bib62","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.08.050_bib63","doi-asserted-by":"crossref","first-page":"16949","DOI":"10.1074\/jbc.M501591200","article-title":"Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells","volume":"280","author":"Langlois","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.08.050_bib64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nsmb886","article-title":"Specific and potent RNAi in the nucleus of human cells","volume":"12","author":"Robb","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib65","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1093\/nar\/gkn693","article-title":"Fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy reveal the cytoplasmic origination of loaded nuclear RISC in vivo in human cells","volume":"36","author":"Ohrt","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1261\/rna.034769.112","article-title":"Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus","volume":"19","author":"Nishi","year":"2013","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2025.08.050_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.celrep.2013.12.013","article-title":"RNAi factors are present and active in human cell nuclei","volume":"6","author":"Gagnon","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.08.050_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.40","article-title":"The MicroRNA Biology of the Mammalian Nucleus","volume":"3","author":"Roberts","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.08.050_bib69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1261\/rna.079500.122","article-title":"RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery","volume":"29","author":"Johnson","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2025.08.050_bib70","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1242\/jcs.073270","article-title":"Stochastic and reversible aggregation of mRNA with expanded CUG-triplet repeats","volume":"124","author":"Querido","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ymthe.2025.08.050_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio","volume":"34","author":"Waldrop","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.08.050_bib72","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","article-title":"5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency","volume":"25","author":"Mueller","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib73","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.08.050_bib74","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jnr.24595","article-title":"Cognitive function and its relationship with brain structure in myotonic dystrophy type 1","volume":"99","author":"Langbehn","year":"2021","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib75","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/dmcn.14161","article-title":"Cognitive and adaptive functioning in congenital and childhood forms of myotonic dystrophy type 1: a longitudinal study","volume":"61","author":"Lindeblad","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/mus.27836","article-title":"Cognitive phenotype of childhood myotonic dystrophy type 1: A multicenter pooled analysis","volume":"68","author":"Sweere","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.08.050_bib77","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fneur.2020.00624","article-title":"Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1","volume":"11","author":"Simoncini","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.700796","article-title":"Cognitive Deficits, Apathy, and Hypersomnolence Represent the Core Brain Symptoms of Adult-Onset Myotonic Dystrophy Type 1","volume":"12","author":"Miller","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib79","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nicl.2016.06.011","article-title":"Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1","volume":"12","author":"Baldanzi","year":"2016","journal-title":"Neuroimage. Clin."},{"key":"10.1016\/j.ymthe.2025.08.050_bib80","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00415-002-0796-z","article-title":"Pattern and significance of white matter abnormalities in myotonic dystrophy type 1: an MRI study","volume":"249","author":"Di Costanzo","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib81","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.nmd.2023.05.010","article-title":"Longitudinal changes in white matter as measured with diffusion tensor imaging in adult-onset myotonic dystrophy type 1","volume":"33","author":"Koscik","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.08.050_bib82","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1038\/s41598-022-07820-1","article-title":"White matter integrity changes and neurocognitive functioning in adult-late onset DM1: a follow-up DTI study","volume":"12","author":"Labayru","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.08.050_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JND-190397","article-title":"Brain Structural Features of Myotonic Dystrophy Type 1 and their Relationship with CTG Repeats","volume":"6","author":"van der Plas","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.08.050_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2018.101615","article-title":"Structural white matter networks in myotonic dystrophy type 1","volume":"21","author":"van Dorst","year":"2019","journal-title":"Neuroimage. Clin."},{"key":"10.1016\/j.ymthe.2025.08.050_bib85","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/WNL.0b013e3181d8c35f","article-title":"Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2","volume":"74","author":"Weber","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.050_bib86","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10072-010-0406-2","article-title":"Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients","volume":"31","author":"Romeo","year":"2010","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ymthe.2025.08.050_bib87","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jns.2017.05.013","article-title":"Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2","volume":"378","author":"Peric","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymthe.2025.08.050_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102078","article-title":"Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1","volume":"24","author":"Labayru","year":"2019","journal-title":"Neuroimage. Clin."},{"key":"10.1016\/j.ymthe.2025.08.050_bib89","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1212\/WNL.0000000000004300","article-title":"Brain imaging in myotonic dystrophy type 1: A systematic review","volume":"89","author":"Okkersen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.050_bib90","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/ene.13062","article-title":"Cognition in myotonic dystrophy type 1: a 5-year follow-up study","volume":"23","author":"Winblad","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nmd.2016.10.003","article-title":"Cognitive decline over time in adults with myotonic dystrophy type 1: A 9-year longitudinal study","volume":"27","author":"Gallais","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.08.050_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30875","article-title":"Neurocognitive disorder in Myotonic dystrophy type 1","volume":"10","author":"Winblad","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ymthe.2025.08.050_bib93","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1212\/WNL.0b013e318260cbe6","article-title":"Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)","volume":"79","author":"Heatwole","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.08.050_bib94","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1093\/nar\/gkg767","article-title":"Structures of trinucleotide repeats in human transcripts and their functional implications","volume":"31","author":"Jasinska","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib95","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1093\/hmg\/ddw266","article-title":"Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice","volume":"25","author":"Carrell","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143465","article-title":"Reversible cardiac disease features in an inducible CUG repeat RNA-expressing mouse model of myotonic dystrophy","volume":"6","author":"Rao","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.08.050_bib97","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/ng1857","article-title":"Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy","volume":"38","author":"Mahadevan","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.08.050_bib98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4939-3271-9_5","article-title":"Design of shRNA and miRNA for Delivery to the CNS","volume":"1382","author":"Toro Cabrera","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib99","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.omtm.2017.12.004","article-title":"Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes","volume":"9","author":"Nass","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.08.050_bib100","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/hum.2009.070","article-title":"Manufacturing recombinant adeno-associated viral vectors from producer cell clones","volume":"20","author":"Thorne","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.050_bib101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-9904-0_10","article-title":"NanoString nCounter Technology: High-Throughput RNA Validation","volume":"2079","author":"Goytain","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.08.050_bib102","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/genes11091109","article-title":"An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I","volume":"11","author":"Lopez-Martinez","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2025.08.050_bib103","series-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1016\/j.ymthe.2025.08.050_bib104","first-page":"3952","article-title":"Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy","volume":"117","author":"Wheeler","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.050_bib105","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/bioinformatics\/bts294","article-title":"OSA: a fast and accurate alignment tool for RNA-Seq","volume":"28","author":"Hu","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.08.050_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf018","article-title":"edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets","volume":"53","author":"Chen","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.050_bib107","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/biomet\/73.3.751","article-title":"An improved bonferroni procedure for multiple tests of significance","volume":"73","author":"Simes","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.ymthe.2025.08.050_bib108","article-title":"pheatmap: Pretty Heatmaps","author":"Kolde","year":"2018","journal-title":"R. Package Version 1.0.12"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:35:20Z","timestamp":1764779720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625007245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525001625007245"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.050","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an AAV-delivered microRNA gene therapy for myotonic dystrophy type 1","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sanofi. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}